Tag Archives: The Medicines Company

Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin

Aug 28, 2012 (Marketwire via COMTEX) –Updated treatment guidelines presented by a leading European acute cardiology expert task force on the management of a severe form of heart attack called ST-segment elevation acute myocardial infarction (STEMI) recommend the use of bivalirudin (The Medicines Company (NASDAQ: MDCO) trade name Angiox┬« in Europe and Angiomax┬« in North […]

Continue Reading

The Medicines Company Expects Cangrelor Phase 3 Trial Enrollment Completion in 2012

Review Committee Recommends Sample Size of 10,900 Patients Based on Interim Analysis PARSIPPANY, NJ, Jul 02, 2012 (MARKETWIRE via COMTEX) –The Medicines Company (NASDAQ: MDCO) today announced it expects to complete patient enrollment of the pivotal Phase 3 CHAMPION PHOENIX trial of cangrelor in fourth quarter of 2012. The Company accepted the recommendation of a […]

Continue Reading

AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease

Global Development and Commercialization Agreement to Begin with Co-Promotion of BRILINTA (ticagrelor) in United States WILMINGTON, Del. & PARSIPPANY, N.J., Apr 25, 2012 (BUSINESS WIRE) –AstraZeneca (NYSE: AZN) and The Medicines Company (NASDAQ: MDCO) announced today a global collaboration for acute ischemic heart disease compounds. Read More

Continue Reading

The Medicines Company Settles Angiomax(R) (Bivalirudin) Patent Litigations With App Pharmaceuticals

PARSIPPANY, NJ, Jan 23, 2012 (MARKETWIRE via COMTEX) –The Medicines Company (NASDAQ: MDCO) today announced that it has settled the lawsuits filed by MDCO in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application (ANDA) filed by APP Pharmaceuticals, LLC (APP) for a generic version of Angiomax(R) (bivalirudin […]

Continue Reading

The Medicines Company’s Cangrelor Bridge Trial Published in the Journal of the American Medical Association

PARSIPPANY, NJ, Jan 17, 2012 (MARKETWIRE via COMTEX) –The Medicines Company (NASDAQ: MDCO) today announced publication in the Journal of the American Medical Association (JAMA) of clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet. The article, “Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery,” is available in the January 18 […]

Continue Reading

The Medicines Company Invests Equity Stake in GeNO, LLC, Nitric Oxide Delivery and Technology Company

Deal Includes Option to License Nitric Oxide Platforms in the Acute Care Setting PARSIPPANY, NJ, Dec 05, 2011 (MARKETWIRE via COMTEX) – The Medicines Company (NASDAQ: MDCO) today announced a non-controlling equity investment in GeNO, LLC (GeNO), an advanced, development-stage technology company that has created unique nitric oxide (NO) generation and delivery technology. In addition […]

Continue Reading

The Medicines Company’s MDCO-216 (ApoA-I Milano Complex) Demonstrates Capacity to Clear Cholesterol From Cells in Preclinical Model

Data Presented at American Heart Association Scientific Sessions 2011 ORLANDO, FL, Nov 14, 2011 (MARKETWIRE via COMTEX) — Researchers from The Medicines Company (NASDAQ: MDCO) today presented the first data of MDCO-216 (ApoA-I Milano Complex) sourced from an improved manufacturing process. MDCO-216 is an investigational, naturally occurring variant of a protein called ApoA-I found in […]

Continue Reading

German Researchers Reaffirm Utility of Angiomax(R)/Angiox(R) (Bivalirudin) in High Risk PCI Patients

Late Breaking ISAR-REACT-4 Results Presented and Published ORLANDO, FL, Nov 13, 2011 (MARKETWIRE via COMTEX) – The ISAR group, world leading cardiology researchers based in Munich, Germany, today simultaneously presented and published results of the 1,721-patient randomized, double-blind, active-controlled, multicenter ISAR-REACT-4 clinical trial in patients with evidence of evolving infarction (heart attack) undergoing percutaneous coronary […]

Continue Reading

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT “Bridging” Stent Patients to Cardiac Surgery SAN FRANCISCO, CA, Nov 09, 2011 (MARKETWIRE via COMTEX) – Late breaking clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet, showed patients can be “bridged” from the time that their physicians […]

Continue Reading

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

The Medicines Company Plans More Research in Emerging Field of Catheter-Based Valve Procedures SAN FRANCISCO, CA, Nov 08, 2011 (MARKETWIRE via COMTEX) – Clinical researchers here reported the first results of a pilot study with the anticoagulant Angiomax (R) (bivalirudin) as an adjunct to catheter-based procedures in patients with severely defective aortic heart valves in […]

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 85 other followers